FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2594-2596 June 15, 2006 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kantarjian, H. PubMed Citation

Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer research and therapy, ranging from the identification of the first specific chromosomal abnormality associated with cancer to the development of imatinib as a specific, targeted therapy for the disease.¹ In this issue of the Journal, two articles^2,3 continue this tradition by describing how an understanding of resistance to imatinib has led to a strategy for circumventing resistance. These articles — one concerning nilotinib and the other dasatinib — are of fundamental importance for at least three reasons. First, they provide immediate hope for patients in whom CML cells . . . [Full Text of this Article]

Source Information

From the Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, Portland, Oreg.

This article has been cited by other articles:

• Ramirez, P., DiPersio, J. F. (2008). Therapy Options in Imatinib Failures. The Oncologist 13: 424-434 [Abstract] [Full Text]  
• Carayol, N., Katsoulidis, E., Sassano, A., Altman, J. K., Druker, B. J., Platanias, L. C. (2008). Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway. J. Biol. Chem. 283: 8601-8610 [Abstract] [Full Text]  
• Fojo, T. (2008). Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better. The Oncologist 13: 277-283 [Full Text]  
• Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., Kocher, T., Superti-Furga, G. (2007). Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063 [Abstract] [Full Text]  
• Pineda, J. R. E. T., Callender, R., Schwartz, S. D. (2007). Ligand Binding and Protein Dynamics in Lactate Dehydrogenase. Biophys. J 93: 1474-1483 [Abstract] [Full Text]  
• Guida, T., Anaganti, S., Provitera, L., Gedrich, R., Sullivan, E., Wilhelm, S. M., Santoro, M., Carlomagno, F. (2007). Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor {beta} Gatekeeper Mutants. Clin. Cancer Res. 13: 3363-3369 [Abstract] [Full Text]  
• Fernandez, A., Sanguino, A., Peng, Z., Crespo, A., Ozturk, E., Zhang, X., Wang, S., Bornmann, W., Lopez-Berestein, G. (2007). Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target. Cancer Res. 67: 4028-4033 [Abstract] [Full Text]  
• Wang, Y., Cai, D., Brendel, C., Barett, C., Erben, P., Manley, P. W., Hochhaus, A., Neubauer, A., Burchert, A. (2007). Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 109: 2147-2155 [Abstract] [Full Text]  
• Kaufmann, S. H. (2006). Imatinib spells BAD news for Bcr/abl-positive leukemias. Proc. Natl. Acad. Sci. USA 103: 14651-14652 [Full Text]  
• Scheindlin, S. (2006). Rare Diseases, Orphan Drugs, and Orphaned Patients. Mol. Interv. 6: 186-191 [Full Text]